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chimerism. Acute graft-versus-host disease occurred in 9 subjects
(2 with grade I, 6 with grade II, 1 with grade III). Chronic
graft-versus-host disease occurred in 8 subjects (5 limited, 3 ex-
tensive). The overall survival was 66% with a median follow up
of 32 months. Four subjects died due to relapse of primary dis-
ease (2 leukemia subjects and 1 Omenn syndrome) and acineto-
bacter septicaemia (1). In conclusion, among malignant diseases,
only the patient with chronic myeloid leukemia survived. Chi-
merism monitoring is essential for post-transplant manage-
ment of persistent detectable recipient hematopoietic cells.
The encouraging result in nonmalignant condition suggests the
beneﬁt of reduced transplant related toxicity and satisfactory
engraftment.
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ALLOGENEIC BLOOD AND MARROW TRANSPLANTATION IN THALAS-
SEMIA MAJOR CLASS 3: AN EXPERIENCE OF IRAN
Ghavamzadeh, A., Iravani, M., Gholibeikian, S., Moradiseresht, M.,
Heydari, P. Hematology-Oncology and BMT Research Center, Tehran,
Islamic Republic of Iran
Objective: Our aim for this study was to describe the outcome of
blood and marrow transplantation in patients with class 3 thalas-
semia major. Method and patients: Since December 1992 till
October 2002, forty-three patients with thalassemia class 3 re-
ceived blood and marrow transplantation from their HLA-identi-
cal siblings. Median age at time of transplantation was 8 years (age
range  3-17), Male/Female  24/19. Twenty-eight patients re-
ceived bone marrow and ﬁfteen patients received peripheral blood
stem cell transplantation. Conditioning regimen was cyclophosph-
amide 40 mg/kg/day (from day–5 to -1) and busulfan 4 mg/kg/day
(from day –9 to -6). GVHD prophylaxis regimen was cyclosporine
A 3mg/kg /day/iv (from day –2 to 5) then 12.5 mg/kg/day/po
(from day5) and methotrexate 10mg/m2 (day1), 6mg/m2 (days
3, 6). Results: Median time of absolute neutrophil count 
0.5  109 /L was on day 20 and Median time of platelet recovery
20 109 /L was on day25. At present 34 out of 43 are alive and
9 patients died due to aGVHD, cGVHD, rejection, veno-occlusive
disease, infection and the others. Thirty-two patients (74.4%)
developed aGVHD (grade I  9, grade II  7, grade III  11,
grade IV  5). Seventeen patients (39.5%) developed cGVHD
(limited  5, extensive  12). Eight year disease free survival in
class 3 and 2 were 71% and 63%, respectively (p  0.3).Eight year
overall survival in class 3 and 2 were 78% and 79%, respectively
(p  0.00). Conclusion: According to this study, for an acceptable
outcome in thalassemia class3. We need better conditioning and
GVHD prophylaxis regimens to decrease cardiopulmonary and
liver complications. The results of blood and marrow transplanta-
tion showed that it is better than supportive therapy such as
transfusion and desferal therapy.
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CELIAC DISEASE TRANSMITTED BY CORD BLOOD STEM CELL TRANS-
PLANTATION (CBST)
Baothman, A.A.1, Correa, H.2, Brown, R.2, Yu, L.C.2 1. King Faisal
Specialist Hospital, Riyadh, Centeral, Saudi Arabia; 2. Louisiana State
University, NewOrleans, LA
Either BMT or CBST could transmit immune associated dis-
eases such as diabetes mellitus, immune thrombocytopenic purpura
and complex autoimmune diseases with Evan’s syndrome and
transverse myelitis. We observed the occurrence of Celiac disease
a year following cord blood stem cell transplantation (CBST) for
acute myelogenous leukemia (AML-FAB M2) in complete second
remission (CR-2). Patient had not suffered celiac disease prior to
CBST and none of family member suffered too. The cord donor
was HLA-identical unrelated male donor with HLA types: A3, B7
(w6), DR (B1), DR (B5), HLA DQ A1.0501 and DQ B1.0201
alleles family history was not available for celiac disease. CBST
complicated with grade 2 skin Graft versus Host Disease (GVHD),
which responded to steroid therapy, a year post transplantation she
developed persistent mucous diarrhea with tinge of blood associ-
ated with abdominal cramps, work up of infectious causes and
studies for CMV enteritis were negative, colonsocopy revealed no
GVHD, gastrointestinal symptoms persist and failed to respond to
steroid and prograf therapy, duodenal and jejunal biopsy revealed
subtotal villous atrophy with cryptic hyperplasia which was sug-
gestive of celiac disease, in addition to, antigliadin IgA, IgG, reti-
culin IgA, and Endomysial IgA antibodies were elevated. She
responded well to gluten-free diet and was symptom-free. Possible
causes of her autoimmune illness were 1) transference of autoim-
mune cells from the donor and 2) patient’s predisposition to au-
toimmune disease secondary to an dysregulated immune system
because of myeloablative therapy. Celiac disease is intolerance to
certain cereal grains causing small bowel villous atrophy and thus
malabsorption. Speciﬁcally, the gliadin component of wheat, and
the prolamin component of rye and barley are implicated in caus-
ing disease by binding to HLA-II class molecules in APC and
hence elicit an immune reaction. Celiac disease is associated with
an increased risk for non-Hodgkin lymphoma, especially of T-cell
type. The propensity to develop T-cell non-Hodgkin lymphoma
and transmission of celiac disease by CBST support T cell concept
in celiac disease. Celiac disease is strongly associated with some
HLA-class II types, including DQA1.0501, and DQB1.0201, in
conjunction with the haplotypes A30, B18, DR3, DRw52, and
DQ2. Autoimmune enteropathy should be considered in HLA-
high risk patients with persistent diarrhea post Stem Cell Trans-
plantation.
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A NOVEL CONDITIONING REGIMEN OF IMMUNE SUPPRESSION WITH
CAMPATH-1H, FLUDARABINE AND MELPHALAN IN STEM CELL TRANS-
PLANTATION FOR NON-MALIGNANT DISORDERS
Barnes, Y.1, Hayashi, R.2, Yu, L.3, DiPersio, J.2, Grossman, W.2,
Witty, S.2, Heigham, M.1, Trinkhaus, K.2, Shenoy, S.2 1. St. Louis
Children’s Hospital, St. Louis, MO; 2. Washington University School of
Medicine, St. Louis, MO; 3. Louisiana State University School of
Medicine, New Orleans, LA
Successful allogeneic stem cell transplantation (SCT) beneﬁts
many non-malignant disorders. Factors limiting successful trans-
plantation for these conditions are lack of HLA matched donors,
toxicities of conditioning, graft rejection, and graft versus host
disease (GVHD). Based on the hypothesis that intense immuno-
suppression targeted at host lymphocytes would allow successful
engraftment of stem cells irrespective of source, we used campath-
1H, ﬂudarabine and melphalan in a novel fashion as conditioning
in a pilot transplant trial for non-malignant disorders. Cam-
path-1H (48 mg total) was administered once daily over 3 days
(-21, -20 and -19), ﬂudarabine (30 mg/m2/day) for 5 days (-8 to -4),
and melphalan (140mg/m2) on day -3. The timing of campath-1H
was designed to deplete recipient lymphocytes and macrophages,
without prolonged immunosuppression of the graft. GVHD pro-
phylaxis was CSA or FK506 (tapered after 3 months), steroids (1
mg/kg) from day -7 (tapered after 1 month), and short course
methotrexate (day 1 [10 mg/m2], 3 and 6 [7.5 mg/m2] except
in cord transplants). Primary end points of the study were engraft-
ment and treatment related mortality (TRM) at 100 days. The
regime was tolerated well. The ﬁrst 10 recipients are described in
table 1. Several recipients with BM failure syndromes were trans-
planted after several platelet and PRBC transfusions, putting them
at high risk for graft rejection. Median follow up was 4 months;
range 1-18m. Neutrophils (ANC 500)/cu.mm) engrafted at 12
days (range 8-20d); platelets (50K/cu mm) engrafted at 22 days
(21-30d). Serial immune reconstitution studies revealed profound
lymphopenia at 1 month (ALC; NK; T and B cells), recovering
after the third month, normalizing at 9 months. Five are off
steroids; 2 are off all immunosuppression. All had stable or im-
proved disease parameters. Post transplant complications were
predominantly infections. All CMV  recipients (n  4) reacti-
vated CMV in  30 days but responded to preemptive therapy.
Others included HHV6 (2) and bacterial (7). One UCB recipient
developed grade 3 toxicity due to CMV disease and TTP, and died
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on day 112. One recipient is pregnant 9 months post transplant.
In summary, this regimen is well tolerated, without increased
TRM or GVHD, and supports engraftment with varied stem cell
sources despite risk factors for graft rejection. Lymphopenia in the
early post transplant period requires close vigilance and early
intervention for infection.
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FREQUENCY AND MAGNITUDE OF DOSE ADJUSTMENT OF IV BUSULFAN
IN TARGETED DOSING STRATEGY FOR PEDIATRIC ALLOGENEIC
TRANSPLANTATION
Grimley, M.S., Taylor, C., Wall, D.A. Texas Transplant Institute, San
Antonio, TX
Busulfan is an important therapuetic agent in pediatric allogeneic
transplantation. The recent introduction of IV busulfan (IV
Busulfex®, ESPpharma) has descreased the intra-and interpatient
dose variations associated with oral absorption and allows for
targeted therapy. Children have increased drug clearance and vary-
ing degrees of hepatic function both developmentally and associ-
ated with the underlying disorders for which they are being
treated. Because of this variability, ﬁrst dose pharmacokinetics
were perfomed on all of our patients to ensure the targeted AUC
was achieved. In a series of 85 consecutive children undergoing
allogeneic transplant at Methodist Children’s Hospital/Texas
Transplant Institute from June 2001 to October 2003, 45 children
received myeloablative doses of busulfan (0.8 mg/kg for patients
3-10 kgs; 1 mg/kg for patients 10 kgs till age 4 yrs; 0.8 mg/kg for
patients  4 yrs given every 6 hours for 16 doses) as part of a
busulfan/cyclophosphamide, busulfan/melphalan or busulfan/ﬂu-
darabine preparative regimen. 42/45 patients had their actual
weight used for dosing calculations. Adjusted IBW was used in 3
patients. All patients received dilantin for seizure prophylaxis. First
dose pharmcokinetics were performed by the Clinical Pharmoki-
netics Lab at Seattle Cancer Care Alliance, targetting an AUC of
900-1300 umol.min, with dose adjustments done starting with dose
7, if needed. Donor source was matched sibling donor bone mar-
row or cord blood in 10 and unrelated donor sources in 35 (2
marrow and 33 mismatched umbilical cord units). The median age
was 4.7 yrs (range 1 month to 17 years). Patients underwent
transplant for a variety of conditions: 12 AML, 5 CML, 1 JMML,
9 ALL, 1 lymphoma, 3 HLH, 10 primary immunodeﬁencies, 4
hematology disorders. No patients developed VOD. 32/33 patients
of patients who received a fully myeloabalative preparative regimen
engrafted. A targeted AUC (900-1300 umoles.min) was achieved
with initial dosing in 50% of the patients. However, many children
required dose adjustment to achieve the targeted AUC, mostly
dose escalation (see table). Given the variability of metabolism in
children, ﬁrst dose pharmacokintics are recommended. Addition-
ally, the starting dose in infants is lower than the currently recom-
mended dose.
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LARGE VOLUME LEUKAPHERESIS FOR AUTOLOGOUS PERIPHERAL
BLOOD STEM CELL COLLECTION IN CHILDREN WEIGHTING LESS THAN
25 KG
Ginani, V.C.1, Cecyn, K.Z.2, Carvalho, M.L.2, Caram, E.1, Macedo,
C.R.P.D.1, Gordan, L.N.1, Gouveia, R.V.1, Bastos, E.M.S.C.1, Del-
buono, E.1, Lee, M.L.M.1, Oliveira, O.M.W.1, Vieira, M.J.1, Seixas,
M.T.3, Petrilli, A.S.1, Seber, A.1 1. Pediatric Oncology Institute-
GRAACC-UNIFESP, Sao Paulo, SP, Brazil; 2. Hematology and He-
matotherapy-UNIFESP, Sao Paulo, SP, Brazil; 3. Pathology Depart-
ment-UNIFESP, Sao Paulo, SP, Brazil
Peripheral blood stem cells (PBSC) are the most frequent source
of hematopoietic stem cells used to rescue patients from high-dose
chemotherapy. The theoretical advantages of PBSC collections are
decreased tumor contamination and faster hematological engraft-
ment after the transplant. Small children are usually not eligible for
such protocols due to little experience of most Hematotherapy
teams, poor venous access and concern with a large extracorporeal
volume. In large volume leukapheresis (LVL) three or more blood
volumes are processed in the same procedure. LVL is also war-
ranted in pediatric patients to decrease the number of procedures
and potentially decrease tumor contamination. Twenty-ﬁve pa-
tients underwent LVL using a Cobe Spectra® cell separator be-
tween 2000-2003. All had the circuit primed with irradiated, ﬁl-
tered and resuspended red blood cells. All patients needed a central
venous catheter placed for the procedure. During the procedure,
the patients received continuous IV infusion with 10% calcium
gluconate 2cc/kg, 10% magnesium sulfate 1 cc/kg, 19.1% potas-
sium chloride 0.3 mEq/kg/hr over four hours to decrease the
adverse effects of ADC infusion. They had vital signs, EKG and
O2 saturation continuously monitored. Patients were 13M:12F
with a median age of 3.5 years-of-age (1-10). The median weight
was 14 kg (8-24). Underlying diagnoses were neuroblastoma (21),
germ cell tumors (2), non-Hodgkin’s lymphoma (1) and alveolar
soft tissue sarcoma (1). The median number of procedures was 2
(1-4). The median total nucleated cell count/kg was 16 (5-66) and
CD34/kg 6 (0.6-71). In conclusion, LVL can be safely performed
in small children if vital signs are adequately monitored and elec-
trolytes are replaced and promptly corrected.
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AUTOLOGOUS STEM CELL TRANSPLANTATION FOR THE TREATMENT
OF PEDIATRIC SOLID TUMORS IN BRAZIL
Castro, C.G.1, Seber, A.2, Mendes, W.3, Castro, H.C.4, Borsato, M.L.4,
Gregianin, L.J.1, Ginani, V.C.2, Barros, J.C.A.4, Petrilli, A.S.2, Bru-
netto, A.L.1 1. Pediatric Oncology Unit-Hospital de Clinicas, Porto
Alegre, RS, Brazil; 2. Pediatric Oncology Institute-GRAACC-
UNIFESP, Sao Paulo, SP, Brazil; 3. Department of Pediatrics-Hospital
A.C. Camargo, Sao Paulo, SP, Brazil; 4. Pediatric Hematology and
Bone Marrow Transplantation Unit-Santa Casa de Sao Paulo, Sao
Paulo, SP, Brazil
High-dose chemotherapy and autologous stem cell rescue can be
used in the treatment of poor prognosis responsive pediatric solid
tumors. Our objective is to describe the experience of four Brazil-
ian hematopoietic stem cell transplantation (HSCT) centers in
Table.
Disease
Age
(years) Source
Cell
dose
(TNC/kg)
Engraft-
ment GVHD
Hurler’s 1.5 BM 3.26  10 (8) donor 0
Langerhan’s 19 S BM 3.38  10 (8) donor Gr1-sk
Thalassemia 10 S BM 2.2  10 (8) BM-d;PB-
mixed
0
Evan’s 12 UCB4/6 1.3  10 (7) donor 0
Aplastic anemia 12 S PB 1.9  10 (10) donor Gr1-sk
Adrenoleukodystrophy 3 S PB 4.58  10 (8) donor 0
Sickle cell anemia 2 S BM 3.3  10 (8) donor 0
Aplastic anemia 20 S BM
5/6
4.2  10 (8) NA 0
Hemophagocytosis 3 S BM 3.7  10 (8) NA 0
Aplastic anemia 32 UCB5/6 2.02  10 (7) NA 0
sk  skin; s  sibling; d  donor; NA  Not available.
Table.
Age/
Weight
Starting
Dose
(mg/kg)
AUC
mol  min:
Median
(range)
Final
Dosing
(mg/kg):
Median
(range)
Percent of
Patients
Requiring
Dose
Adjustment
Dose
Increased/
Dose
Decreased
3-10 kg
(n  12) 0.8 1167 (825-1869) 0.93 (0.67-1.25) 50%-6/12 pts 41/22
10 kg-4 years
(n  11) 1 1142 (908-1518) 1 (0.76-1.25) 27%-3/11 21/12
>4 years
(n  22) 0.8 1089 (620-1827) 0.82 (0.57-1.25) 65%-15/23 111/42
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